Cargando…

Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas

Detalles Bibliográficos
Autores principales:	Riviere-Cazaux, Cecile, Lacey, Jean M, Carlstrom, Lucas P, Laxen, William J, Munoz-Casabella, Amanda, Hoplin, Matthew D, Ikram, Samar, Zubair, Abdullah Bin, Andersen, Katherine M, Warrington, Arthur E, Decker, Paul A, Kaufmann, Timothy J, Campian, Jian L, Eckel-Passow, Jeanette E, Kizilbash, Sani H, Tortorelli, Silvia, Burns, Terry C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259246/ https://www.ncbi.nlm.nih.gov/pubmed/37313502 http://dx.doi.org/10.1093/noajnl/vdad061

Ejemplares similares

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

TIPS-07 LONGITUDINAL CSF PROTEOMICS FOR MONITORING AND PHARMACODYNAMIC BIOMARKER DISCOVERY
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2023)

Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma
por: Nakagawa, Makoto, et al.
Publicado: (2022)

CLRM-14 INTRATUMORAL EXTRACELLULAR METABOLIC IMPACT OF DFMO AND AMXT 1501 IN LIVE HUMAN GLIOMAS
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2022)

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients
por: Choi, Changho, et al.
Publicado: (2012)

The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
por: Wang, Tian-Xiang, et al.
Publicado: (2019)

D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice
por: Akbay, Esra A., et al.
Publicado: (2014)

Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity
por: Chittaranjan, Suganthi, et al.
Publicado: (2014)

Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas
por: Leather, Thomas, et al.
Publicado: (2017)

(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas
por: Richardson, Leland G., et al.
Publicado: (2019)

Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2023)

Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production
por: Kotredes, Kevin P., et al.
Publicado: (2019)

Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner
por: Viswanath, Pavithra, et al.
Publicado: (2018)

Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry
por: Longuespée, Rémi, et al.
Publicado: (2018)

The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo
por: Suijker, Johnny, et al.
Publicado: (2015)

DDRE-27. IDH MUTATED GLIOMAS PROMOTE EPILEPTOGENESIS VIA D-2-HYDROXYGLUTARATE DEPENDENT MTOR HYPERACTIVATION
por: Mortazavi, Armin, et al.
Publicado: (2021)

Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
por: Fiehn, Oliver, et al.
Publicado: (2016)

Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
por: Showalter, Megan Reed, et al.
Publicado: (2017)

An untapped window of opportunity for glioma: targeting therapy-induced senescence prior to recurrence
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2023)

D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth
por: Ma, Shenghong, et al.
Publicado: (2015)

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate
por: Andronesi, Ovidiu C., et al.
Publicado: (2018)

OTME-4. IDH mutated gliomas promote epileptogenesis via D-2-hydroxyglutarate dependent mTOR hyperactivation
por: Mortazavi, Armin, et al.
Publicado: (2021)

Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas
por: Autry, Adam W., et al.
Publicado: (2022)

Bilateral subdural hematomas and retinal hemorrhages mimicking nonaccidental trauma in a patient with D‐2‐hydroxyglutaric aciduria
por: Perales‐Clemente, Ester, et al.
Publicado: (2020)

The Roles of 2-Hydroxyglutarate
por: Du, Xin, et al.
Publicado: (2021)

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
por: Mu, Luyan, et al.
Publicado: (2018)

Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells
por: Hujber, Zoltán, et al.
Publicado: (2017)

Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate
por: Sesanto, Rae, et al.
Publicado: (2021)

Serum D‐2‐hydroxyglutarate and the ratio of D‐2HG/L‐2HG predict IDH mutation in acute myeloid leukemia
por: Zhang, Chelsea, et al.
Publicado: (2023)

Urine 2-Hydroxyglutarate in Glioma
por: Lombardi, Giuseppe, et al.
Publicado: (2016)

2-Hydroxyglutarate in Cancer Cells
por: Ježek, Petr
Publicado: (2020)

D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH
por: Oizel, K, et al.
Publicado: (2015)

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model
por: Wang, Fang, et al.
Publicado: (2016)

Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells
por: Badur, Mehmet G., et al.
Publicado: (2018)

Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells
por: Badur, Mehmet G., et al.
Publicado: (2018)

Detection of 2-Hydroxyglutarate by 3.0-Tesla Magnetic Resonance Spectroscopy in Gliomas with Rare IDH Mutations: Making Sense of “False-Positive” Cases
por: Natsumeda, Manabu, et al.
Publicado: (2021)

Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
por: Li, Luyuan, et al.
Publicado: (2015)

MPC-11 IDH1/2 MUTATIONS ARE ASSOCIATED WITH SEIZURE ONSET AND VETRY IMAGING IN PATIENTS WITH DIFFUSE GLIOMA VISUALIZING 2-HYDROXYGLUTARATE BY MASS SPECTRUM
por: Ohno, Makoto, et al.
Publicado: (2019)

Progress in understanding 2-hydroxyglutaric acidurias
por: Kranendijk, Martijn, et al.
Publicado: (2012)

The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas
por: Reiter-Brennan, Cara, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kbau6nbvfu3i8kjdftqbrlio85